Our Product

About Coxor™

Rapid onset of action

Coxor™ is a powder and solvent for oral solution for emergency treatment for suspected acute myocardial infarction. This medicine is used in adults above 18 years for suspected acute myocardial infarction (heart attack) after contact with emergency medical services.

In case of symptoms of a suspected acute myocardial infarction, the patient should call the national rescue number as soon as possible. If advised to do so by the emergency medical services, 300 mg of Coxor™ should be taken as quickly as possible.

The content is to be drunk following reconstitution. The powder is to be dissolved in the solvent and shaken until it is dissolved.

Medicinal product not subject to medical prescription

Design
Coxor is designed to be ready-to-use and simple to self-administer for at-risk patient groups.
Production
Asamedic started production of the drug in the fall of 2018 and set 6,000 vials in stability program. Full scale production started november 2020.
DCP
DCP well-established use application was submitted in December 2019, with Norway as RMS and Denmark as CMS.
Positive outcome
End of procedure with a positive outcome took place in January 2021.
Coxor™ enables immediate intake of acetylsalicylic acid
2

Coxor™ enables immediate intake of acetylsalicylic acid without needing a glass of water and does not depend on the patient’s saliva production.

3

Coxor™ is the first dedicated emergency OTC approved product against heart attack with appropriate user properties.

Highlights

Positive results

Positive results on 18 months stability study, voluntary clinical trial completed. Favorable study results expected to be published H1 2022.

Secure patent protection

Extensive investment projects and studies performed to secure patent protection — patent approved in Europe, Australia, India and several other countries. Patent pending in numerous jurisdictions throughout the world.

Testimonials

The readily available acetylsalicylic acid with rapid onset offered by Asamedic's product will have a significantly positive effect on users' chance to survive in the case of acute myocardial infarction, as well as on the risk of delayed injuries. Everyone in the risk group, as well as their next of kin, should keep this product at hand as a type of ‘life insurance’

Dan Atar, a world-leading expert in the field of myocardial infarction
ISCHAEMIC HEART DISEASE
Leading cause

The world’s biggest killer is ischaemic heart disease, responsible for 16% of the world’s total deaths. Since 2000, the largest increase in deaths has been for this disease, rising by more than 2 million to 8.9 million deaths in 2019.

15 people die every minute

from a heart attack (that’s 4 times more lives than Covid-19 has taken in the past year). In the US alone a person has a heart attack every 40 seconds. Studies show that prolonged delays often occur before inhospital therapy , and that prehospital treatment with the appropriate drug could save lives and reduce after-effects.
WHO, 2020. Read 02.15.2021